A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients With Chronic Lymphocytic Leukemia (Cll) Who Are Intolerant to Prior BTK or Pi3k Delta Inhibitor Therapy
Hematological Oncology - United Kingdom
doi 10.1002/hon.56_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley